Fatemeh-Sadat Tabatabaei - MD, Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Arefeh Saeedian - MD, Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran- Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Amirali Azimi - MD, Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran-School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Kasra Kolahdouzan - MD, Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Background: Cervical cancer, the most common gynecological cancer, is a matter of concern, especially in developing countries. The present study investigates survival rates, associated factors, and post-treatment follow-up status in cervical cancer patients. Study Design: A retrospective cohort study. Methods: This study was conducted on ۱۸۷ patients referred to an academic referral cancer center in Iran from ۲۰۱۴-۲۰۲۰. Overall survival (OS) and event-free survival (EFS) were evaluated using Kaplan Meyer analysis. The event was defined as recurrence, metastasis, or death. Results: The patients came for post-treatment visits for a median of ۳۶ months (interquartile range [IQR]: ۱۸-۵۱). The median OS and EFS were ۲۴ and ۱۸ months, respectively. The ۱- and ۳- year OS rates were ۹۰% and ۷۲%, respectively. The ۱- and ۳- year EFS rates were ۷۶% and ۶۱%, respectively. Stage ≥ III (hazard ratio [HR]: ۳.۱, ۹۵% confidence interval [CI]: ۱.۵, ۶.۵, P < ۰.۰۰۱) and tumor size > ۴ cm (HR: ۲.۵, ۹۵% CI: ۱.۲, ۴.۹, P = ۰.۰۰۶) predicted lower OS. The most common histopathology was squamous cell carcinoma (SCC) (۷۱.۱%) with non-significant higher ۳- year OS (HR: ۰.۶۲, ۹۵% CI: ۰.۳۳, ۱.۱۶, P = ۰.۱۳). No significant difference in OS was found between adjuvant and definitive radiotherapy in both early and advance-staged patients (Log-rank = ۰.۷ P = ۰.۴, log-rank = ۱.۶, P = ۰.۲, respectively). Conclusion: As evidenced by the obtained results, the survival of patients was lower compared to that in developed countries. Higher stage and tumor size led to shorter survival. The histopathology and type of treatment in comparable stages did not have any significant impact on survival.

Neoplasm Staging, Survival Analysis, Adjuvant Radiotherapy, Uterine Cervical Neoplasm